fda ban on tirzepatide reconsidering its decision to take off its drug shortage list FDA moves to remove GLP-1

Ill be watching the rulemaking process closely, and Ill update here the moment theres real movement A note on scope: this piece is about regulatory status, not personal medical guidance

Adipose tissue reduction decreases free fatty acid flux to the liver, which lowers hepatic triglyceride synthesis and VLDL secretion

Less availability of GSH will further increase the oxidative stress in the cell, which in turn will favor S protein-ACE2 interactions and enhance the severity of COVID-19 infection

doi: 10.1002/edm2.163 23 ZhangLYangMRenHHuHBodenGLiLet al

Body composition monitoring provides valuable feedback during treatment